Small Cap: Bionics to Test Anti-Cancer Drug on Humans (Australia)
This article was originally published in PharmAsia News
Executive Summary
Biotechnology company, Bionomics Limited, will soon initiate clinical trials of a new cancer treatment in Australia. The company's Nov. 22 announcement comes on the heels of the approval of its Investigational New Drug application by the U.S. FDA. The application will also pave the way for further clinical tests of the experimental drug in both Australia and the United States. As a result of the announcement, South Australia-based Bionomics saw its shares rise 7 percent. The new treatment, called BNC105, employs a cancer-fighting method designed to destroy tumors by cutting off their blood supply. BNC105 is just one of Bionomics experimental cancer treatments. In addition to cancer research, the company has also started drug discovery and development programs for multiple sclerosis, anxiety and epilepsy. (Click here for more